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type (Del19 or L858R) and brain metastases (presence/absence).
There were 3 co-primary endpoints: progression free survival
(PFS) by independent review, time to treatment failure (TTF)
and overall survival (OS). Secondary endpoints included objective
response rate (ORR), disease control rate, tumour shrinkage and
safety.
Results: Pts received daily afatinib (40mg; n = 160) or gefitinib
(250mg; n = 159) until radiological disease progression or beyond
if deemed beneficial by investigator. Baseline characteristics were
balanced in treatment arms (Asian: 58.8% vs 55.3%, EGFR Del19:
57.5% vs 58.5%), respectively, with slightly more females in
the gefitinib arm (56.9% vs 66.7%). PFS was significantly
improved with afatinib vs gefitinib (HR=0.73; 95% CI, 0.57–0.95;
p = 0.017), as was TTF (HR=0.73; 95% CI, 0.58–0.92; p = 0.007).
Consistent treatment benefit was seen across the subgroups
including mutation type and race. Independently assessed ORR
was significantly higher with afatinib vs gefitinib (70% vs 56%,
p = 0.008). OS data are not mature. Common grade 3 related
adverse events (AEs) were: diarrhoea (12.5%) and rash/acne
(9.4%) with afatinib, and alanine aminotransferase increase
(8.2%) with gefitinib. There was no drug-related interstitial lung
disease for afatinib (vs 4 gefitinib pts; 2.5%). Discontinuation due
to drug-related AEs was the same in each arm (6.3%).
Conclusions: Afatinib significantly improved PFS compared with
gefitinib as first-line treatment of EGFRm+ pts. Afatinib treatment
benefit was also seen for TTF and ORR. The AE profiles for
both drugs were manageable and discontinuation due to AEs was
equally low.
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Whole body and intracranial efficacy of ceritinib
in patients (pts) with crizotinib (CRZ) pretreated,
ALK-rearranged (ALK+) non-small cell lung cancer
(NSCLC) and baseline brain metastases (BM): Results from
ASCEND-1 and ASCEND-2 trials
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Background: BM are a common site of disease progression in
pts with ALK+ NSCLC, including those who have received CRZ.
Ceritinib is a selective oral ALK inhibitor with a 20-fold greater
potency than CRZ in vitro. Here we present efficacy outcomes in
pts with CRZ pretreated ALK+ NSCLC and baseline BM, treated
with ceritinib in the ASCEND-1 (phase 1) and ASCEND-2 (phase 2)
trials.
Methods: In both trials, pts with CRZ pretreated, ALK+ NSCLC
and clinically / neurologically stable baseline BM received oral
ceritinib 750mg/day; the majority of pts had also received
chemotherapy. CT/MRI scans were performed in pts at baseline
and every 6 (ASCEND-1) or 8 (ASCEND-2) weeks thereafter.
Efficacy analyses (by Blinded Independent Review Committee
[BIRC]) assessed whole body responses according to Response
Evaluation Criteria in Solid Tumors (RECIST) 1.0 and 1.1 criteria
for ASCEND-1 and ASCEND-2, respectively. Pooled intracranial
responses, by BIRC, were evaluated (retrospectively in ASCEND-1;
prospectively in ASCEND-2) in pts with measureable BM at
baseline according to RECIST 1.1 criteria.
Results: Of the 98 and 100 CRZ pretreated pts with baseline
BM enrolled in the ASCEND-1 and ASCEND-2 trials, respectively,
69.4% and 72.0% had received prior radiotherapy to the brain.
Ceritinib showed efficacy in the whole body and in brain
metastases (Table 1). Tolerability was acceptable. The most
common AEs (any grade, regardless of study drug relationship)
were (ASCEND-1; ASCEND-2) nausea (83.7%; 82.0%), diarrhea
(76.5%; 82.0%) and vomiting (60.2%; 64.0%); 10 and 7
pts discontinued due to AEs from ASCEND-1 and ASCEND-2,
respectively.
Conclusions: Ceritinib treatment resulted in clinically meaningful
whole body and intracranial activity with an acceptable
tolerability profile in pts with CRZ pretreated, ALK+ NSCLC and
baseline BM.
Clinical trial identification: NCT01283516 (ASCEND-1);
NCT01685060 (ASCEND-2)
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Table 1 (abstract 141PD).
ASCEND-1 ASCEND-2
Data cut-off 14 Apr 2014 13 Aug 2014
Number of patients with BM at baseline 98 100
Duration of follow-up, months (range) 9.8 (0.1–22.2) 11.2 (0.2–18.9)
Whole body response per BIRC
Overall response rate, % [95% CI] 41.8 [31.9, 52.2] 32.0 [23.0, 42.1]
Disease control rate, % [95% CI] 69.4 [59.3, 78.3] 64.0 [53.8, 73.4]
Median duration of responsea, months [95% CI] 8.2 [5.6, 13.1] 9.3 [5.5, 12.9]
Median progression-free survival, months [95% CI] 6.7 [5.4, 9.5] 6.8 [5.4, 7.4]
Intracranial response per BIRC Pooled
Number of patients with measurable BM at baseline 28 33 61
Overall intracranial response rate, % [95% CI] 35.7 [18.6, 55.9] 39.4 [22.9, 57.9] 37.7 [25.6, 51.0]
Intracranial disease control rate, % [95% CI] 60.7 [40.6, 78.5] 84.8 [68.1, 94.9] 73.8 [60.9, 84.2]
Median intracranial duration of responsea, months [95% CI] 11.1 [2.8, NE] 12.8 [4.0, 13.2] 12.8 [6.9, NE]
NE, non-evaluable.
a Duration of response calculated for patients with confirmed complete or partial response CI, confidence interval.
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The impacts on work productivity from ceritinib compared
with chemotherapy for crizotinib-experienced ALK+
non-small cell lung cancer
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Background: Ceritinib has demonstrated rapid and durable
antitumor activity in ALK+ non-small cell lung cancer (NSCLC).
Table (abstract 142PD): Per-patient and total societal impacts on productivity of ceritinib vs. chemotherapy for the EU5 countries over
5 years
UK France Germany Italy Spain
Productivity gain per patient (working day) 70 67 68 65 65
Societal cost saving per patient (2014 euro) € 12,420 €18,641 €17,150 €14,656 €11,058
Total societal productivity gain (working day) 33,528 31,989 40,734 29,422 20,495
Total societal saving (2014 euro) € 5,981,367 €8,854,670 €10,232,265 €6,661,244 €3,492,396
This study projected the work productivity gain and its associated
societal impact of ceritinib as compared to chemotherapy for
patients with crizotinib-experienced ALK+ NSCLC in the EU5
countries.
Methods: An economic model was built to estimate the
probabilities of ALK+ NSCLC patients being at stable, progressive
disease, or death state in each monthly cycle based on efficacy
inputs from clinical trials for ceritinib and from literature
for chemotherapy. Labor costs and probabilities of restoring
work productivity, based on inputs from public databases or
publications, were incorporated to calculate work productivity
for patients and their informal caregivers, and compared between
patients initiating ceritinib vs. chemotherapy over a 5-year time
horizon. Model parameters were varied in one-way sensitivity
analyses.
Results: Compared to chemotherapy, ceritinib treatment was
associated with 65 (Italy) to 70 (UK) additional working days per
patient (including associated caregiver) over 5 years. Societal cost
savings per patient due to work productivity gain ranged from
€11,058 (Spain) to €18,641 (France). Across countries, 54–61%
of these gains occurred for treated patients, while the remainder
occurred for their informal caregivers. At the country level, the
societal savings from ceritinib ranged from €3.5 to 10.2 million.
The results were robust under sensitivity analyses.
Conclusions: Ceritinib treatment for crizotinib-experienced ALK+
NSCLC was associated with greater work productivity for patients
and their informal caregivers compared to treatment with
chemotherapy. These savings represent an economic benefit of
ceritinib treatment from the societal perspective, which would
occur in addition to clinical and quality-of-life benefits and
impacts on medical expenditures.
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